Collegium Pharmaceutical (COLL) Gross Profit (2016 - 2026)

Collegium Pharmaceutical's Gross Profit history runs 11 years deep, the most recent figure standing at $117.2 million for Q1 2026.

• In Q1 2026, Gross Profit rose 20.47% year-over-year to $117.2 million; the TTM figure through Mar 2026 stood at $483.2 million (up 26.09% YoY), while the FY2025 annual figure was $463.3 million, up 22.77% from the prior year.
• Gross Profit was $117.2 million for Q1 2026 at Collegium Pharmaceutical, down from $128.4 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $129.2 million in Q3 2025 to a low of $48.5 million in Q1 2022.
• Historically, Gross Profit has averaged $87.9 million across 5 years, with a median of $91.5 million in 2024.
• Biggest YoY gain for Gross Profit was 3835.11% in 2022; the steepest drop was 12.77% in 2022.
• A 5-year view of Gross Profit shows it stood at $49.8 million in 2022, then jumped by 90.06% to $94.6 million in 2023, then climbed by 3.87% to $98.3 million in 2024, then surged by 30.61% to $128.4 million in 2025, then retreated by 8.67% to $117.2 million in 2026.
• The last three Gross Profit figures came in at $117.2 million (Q1 2026), $128.4 million (Q4 2025), and $129.2 million (Q3 2025), per Business Quant data.